Bausch Health Companies Inc. (T:BHC*CA)

Business Focus: Pharmaceuticals (NEC)

Apr 11, 2024 04:22 pm ET

Bausch Health to Announce First-Quarter 2024 Results on May 2

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Apr 11, 2024 01:03 pm ET

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbrevi

Apr 11, 2024 11:17 am ET

Canadian Investment Regulatory Organization Trade Resumption - BHC

TORONTO, April 11, 2024 /CNW/ - Trading resumes in:

Apr 11, 2024 11:03 am ET

Canadian Investment Regulatory Organization Trading Halt - BHC

TORONTO, April 11, 2024 /CNW/ - The following issues have been halted by CIRO:

Apr 11, 2024 08:00 am ET

Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% w/w), is now available to patients through BC PharmaCare, the public drug program of British Columbia.

Apr 05, 2024 06:15 pm ET

Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals

LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals of New York, LLC, Amneal EU, Limited, Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals Private Limited, and Amneal Pharmaceuticals, Inc. This lawsuit follows receipt of a Notice of Paragraph IV Certification stating that Amneal submitted an Abbreviated New Drug Application (ANDA)

Apr 03, 2024 12:05 pm ET

Canadian Investment Regulatory Organization Trade Resumption - BHC

TORONTO, April 3, 2024 /CNW/ - Trading resumes in:

Apr 03, 2024 12:01 pm ET

Canadian Investment Regulatory Organization Trading Halt - BHC

TORONTO, April 3, 2024 /CNW/ - The following issues have been halted by CIRO:

Apr 03, 2024 08:00 am ET

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative

LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.1

Apr 02, 2024 08:00 am ET

Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversation

Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact Report

Mar 06, 2024 08:00 am ET

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients with resectable head and neck squamous cell carcinoma. An IIS is a study that is proposed, developed, and conducted by a qualified sponsor external to Bausch Health/Salix who assumes full responsibility for the study.

Mar 05, 2024 08:00 am ET

New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure

Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey

Mar 01, 2024 08:00 am ET

Bausch Health Companies to Present at Cowen Annual Health Care Conference

LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference in Boston on March 5, 2024. The Bausch Health team will be hosting a fireside chat at 12:50 p.m. EST, and a live webcast will be accessible through the Investor Relations section of the Bausch Health website at https://ir.bauschhealth.com/. A replay of the webcast will be posted after the presentation and will be available for a limited ti

Feb 22, 2024 07:00 am ET

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

LAVAL, QC / ACCESSWIRE / February 22, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth-quarter and full-year 2023 financial results.

Feb 12, 2024 08:00 am ET

Salix Announces 2024 Gastrointestinal Health Scholars Program

Salix to Provide Scholarships to 10 Students Living with GI Diseases

Feb 01, 2024 04:10 pm ET

Bausch Health Announces Board Refreshment

LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced, as part of its ongoing commitment to board refreshment and board diversity, its nomination of two independent and diverse candidates to stand for election to its Board of Directors at the Company's 2024 Annual Meeting of Shareholders: Christian A. Garcia, Former Executive Vice President and Chief Financial Officer of BrandSafway Industries, LLC, and Frank D. Lee, Chief Executive Officer of Pacira Biosciences, Inc.

Feb 01, 2024 08:00 am ET

Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22

LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023 financial results on Thursday, Feb. 22, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Jan 30, 2024 08:00 am ET

CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.

LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin, adapalene, benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1% indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Jan 18, 2024 04:50 pm ET

CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets

Jan 18, 2024 08:00 am ET

Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets

Jan 08, 2024 12:00 am ET

Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

LAVAL, QC / ACCESSWIRE / January 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, as scheduled, oral arguments were heard today at the U.S. Court of Appeals for the Federal Circuit (the "Court") in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. As expected, no ruling was issued by the Court following these oral arguments.

Dec 21, 2023 07:00 am ET

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

Trial Meets Both Primary and Key Secondary Endpoints

Dec 18, 2023 08:00 am ET

DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan

LAVAL, QC / ACCESSWIRE / December 18, 2023 / Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), ("Bausch Health" or the "Company") today announced that DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene), the company's novel topical prescription drug for improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe disease,1 is now available to patients enrolled in Quebec's public drug plan operated by the Régie de l'assurance maladie du Québec (RAMQ)

Dec 05, 2023 08:00 am ET

Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day

BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition.

Nov 10, 2023 08:00 am ET

The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, Accor

Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE diagnosis

Nov 10, 2023 12:00 am ET

CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate

This corrects and replaces the release that was disseminated earlier today

Nov 08, 2023 08:00 am ET

As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)

Company Introduces Multimedia Resources to Bring Awareness of SAD

Nov 02, 2023 07:00 am ET

Bausch Health Announces Third-Quarter 2023 Results

LAVAL, QC / ACCESSWIRE / November 2, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2023 financial results and other key updates from the quarter.

Nov 01, 2023 12:22 pm ET

U.S. District Court Dismisses Norwich's Lawsuit Against the FDA

LAVAL, QC / ACCESSWIRE / November 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced that the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Becerra, et al. (Case No. 23-cv-01611), denied Norwich Pharmaceuticals, Inc.'s (Norwich) motion in their lawsuit against the U.S. Food and Drug Administration (FDA). Norwich had asked the District Court to direct the FDA to immediately grant Final Approval to Norwich's Abbreviated New Drug Appl

Nov 01, 2023 10:43 am ET

Canadian Investment Regulatory Organization Trade Resumption - BHC

TORONTO, Nov. 1, 2023 /CNW/ - Trading resumes in:

Nov 01, 2023 10:40 am ET

Canadian Investment Regulatory Organization Trading Halt - BHC

TORONTO, Nov. 1, 2023 /CNW/ - The following issues have been halted by CIRO:

Oct 26, 2023 08:00 am ET

Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)

First-Ever Television Ad Campaign for APLENZIN® (bupropion hydrobromide) Airs in October

Oct 20, 2023 05:20 pm ET

FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

First and only FDA-approved fixed-dose, triple-combination topical treatment

Oct 17, 2023 08:00 am ET

New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk

Hurdles Led to Almost All Patients Having At Least One Day Delay to Receive Treatment with Xifaxan®

Oct 12, 2023 08:00 am ET

Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2

LAVAL, QC / ACCESSWIRE / October 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thursday, Nov. 2, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Oct 10, 2023 08:00 am ET

Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.

LAVAL, QC / ACCESSWIRE / October 10, 2023 / Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021. The report, based on a survey of 400 health care providers (HCPs) who treat CLD, qualitative interviews with HCPs and secondary research from peer-reviewed p

Oct 04, 2023 08:00 am ET

Salix Pharmaceuticals Partners with Bellamy Young

Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting Hepatic Encephalopathy

Sep 29, 2023 10:15 am ET

Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)

LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company" or "Bausch Health") (NYSE/TSX:BHC), today announced it has completed its acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

Sep 21, 2023 08:00 am ET

League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease

Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum Disease

Sep 18, 2023 05:45 pm ET

Bausch Health Announces CFO Transition Plan

LAVAL, QC / ACCESSWIRE / September 18, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("BHC" or the "Company") today announced that Tom Vadaketh, Executive Vice President, Chief Financial Officer, has resigned from his role to pursue another opportunity, and will be leaving the Company effective October 13, 2023. The Company thanks Mr. Vadaketh for his significant contributions and leadership during a period of transition at the Company.

Sep 12, 2023 08:00 am ET

New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce that following its approval by Health Canada the new treatment PrUCERIS® (budesonide) aerosol foam is now available across Canada to treat mild to moderate distal ulcerative colitis in adults.

Sep 11, 2023 08:00 am ET

Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)

LAVAL, QC / ACCESSWIRE / September 11, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company") (NYSE/TSX:BHC), announced today that, in connection with the financing of its pending acquisition (the "Acquisition") of XIIDRA® and certain other ophthalmology assets, Bausch + Lomb Escrow Corp. (the "Escrow Issuer"), a wholly owned subsidiary of Bausch + Lomb, launched an offering of $1.4 billion aggregate principal amount of new senior secured notes due 2028 (the &

Sep 06, 2023 06:16 pm ET

Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)

LAVAL, QC / ACCESSWIRE / September 6, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has disclosed certain historical and pro forma financial information with respect to its previously announced proposed acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (the "Acquisition") on a Current Report on Form 8-K and on its SEDAR+ (www.sedarplus.ca) profile. In connection with the Acquisition, as previ

Aug 03, 2023 07:00 am ET

Bausch Health Announces Second-Quarter 2023 Results, Other Key Updates From the Quarter, and Raises Full-Year 2023 Revenue Outlook

LAVAL, QC / ACCESSWIRE / August 3, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second-quarter 2023 financial results and various other key updates from the quarter.

Jul 27, 2023 08:00 am ET

Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients

Scholarships Awarded to Six Students Affected by Dermatologic Conditions

Jul 13, 2023 08:00 am ET

Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3

LAVAL, QC / ACCESSWIRE / July 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release its second-quarter financial results on Thursday, Aug. 3, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Jul 11, 2023 08:00 am ET

Salix Announces 2023 Gastrointestinal Health Scholars Program Winners

For Fourth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship

Jul 07, 2023 08:00 am ET

OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference

Oral Health Care Companies Celebrate the 100th ADHA Conference by Highlighting New Data for the Treatment of Periodontal Disease

Jul 07, 2023 07:00 am ET

Bausch Health Enters Into $600 Million Financing Facility With KKR

LAVAL, QC / ACCESSWIRE / July 7, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health.

Jun 30, 2023 08:30 am ET

Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)

LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye.

Jun 19, 2023 08:00 am ET

Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023

Three XIFAXAN® (rifaximin) Research Posters to Be Featured

Jun 06, 2023 08:00 am ET

Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration

LAVAL, QC / ACCESSWIRE / June 6, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, understand that in a June 2, 2023, letter, the U.S. Food and Drug Administration (FDA) granted Norwich Pharmaceuticals Inc. Tentative Approval of its Abbreviated New Drug Application (ANDA) for XIFAXAN® (rifaximin) 550 mg. At the same time, the FDA confirmed in its Letter that it cannot grant Final Approval until Oct. 2, 2029 - the date specified by the presiding judge in his Final Judgment in Salix Pharmaceuticals, L

May 18, 2023 08:00 am ET

New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis

Novel Trial to Study the Reduction of Certain Pathogens Following Scaling and Root Planing Procedure

May 17, 2023 01:33 pm ET

IIROC Trade Resumption - BHC

TORONTO, May 17, 2023 /CNW/ - Trading resumes in:

May 17, 2023 01:20 pm ET

U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied Norwich Pharmaceuticals' motion to modify the Court's final judgment that prevents the U.S. Food and Drug Administration (FDA) from approving Norwich's abbreviated new drug application (ANDA) for XIFAXAN® (rifaximin) 550 mg before Oct. 2, 2029. As a result of this decision, No

May 17, 2023 01:17 pm ET

IIROC Trading Halt - BHC

TORONTO, May 17, 2023 /CNW/ - The following issues have been halted by IIROC:

May 17, 2023 12:46 pm ET

IIROC Trade Resumption - BHC

TORONTO, May 17, 2023 /CNW/ - Trading resumes in:

May 17, 2023 12:43 pm ET

ttIIROC Trading Halt - BHC

TORONTO, May 17, 2023 /CNW/ - The following issues have been halted by IIROC:

May 17, 2023 12:41 pm ET

IIROC Trading Halt - BHC

TORONTO, May 17, 2023 /CNW/ - The following issues have been halted by IIROC:

May 17, 2023 08:00 am ET

Bausch Health Announces 2023 Annual Meeting of Shareholder Results

LAVAL, QC / ACCESSWIRE / May 17, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2023 annual meeting of shareholders (the "Annual Meeting").

May 10, 2023 08:00 am ET

Bausch Health Observes Mental Health Awareness Month

LAVAL, QC / ACCESSWIRE / May 10, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is proud to recognize May as Mental Health Awareness Month by continuing efforts that highlight the importance of educating and supporting those with mental health care needs.

May 08, 2023 08:00 am ET

Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023

Five XIFAXAN® (rifaximin) and TRULANCE® (plecanatide) Research Posters Also to Be Presented

May 04, 2023 07:00 am ET

Bausch Health Announces First-Quarter 2023 Results

LAVAL, QC / ACCESSWIRE / May 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first-quarter 2023 financial results.

May 03, 2023 06:58 am ET

RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada

New treatment from Bausch Health, Canada indicated to treat seasonal allergy and associated ocular symptoms in adults, adolescents and children 6 years and older

May 01, 2023 08:00 am ET

Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel

PDUFA Action Date is October 20, 2023

Apr 24, 2023 08:00 am ET

Salix Partners with the Colorectal Cancer Alliance on Community Screening Program

Program Seeks to Increase the Number of People Screened to Help Prevent Colorectal Cancer Diagnoses in Philadelphia

Apr 13, 2023 08:00 am ET

Bausch Health to Announce First-Quarter 2023 Results on May 4

LAVAL, QC / ACCESSWIRE / April 13, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Apr 04, 2023 08:00 am ET

New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider

Salix Pharmaceuticals Releases Third Annual Patient Perspectives Report

Mar 01, 2023 08:00 am ET

Bausch Health Announces Changes to its Board of Directors

LAVAL, QC / ACCESSWIRE / March 1, 2023 / Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) today announced that Richard De Schutter and Dr. Argeris Karabelas are retiring from the Company's Board of Directors, effective as of the upcoming 2023 annual meeting of shareholders of the Company. Following the retirements of Mr. De Schutter and Dr. Karabelas, the size of the Board will be reduced to 10 directors.

Feb 23, 2023 07:00 am ET

Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results

LAVAL, QC / ACCESSWIRE / February 23, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced its fourth-quarter and full-year 2022 financial results.

Feb 13, 2023 08:00 am ET

Salix Announces 2023 Gastrointestinal Health Scholars Program

Salix to Provide Scholarships to 10 Students Living with GI Diseases

Feb 01, 2023 08:00 am ET

Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23

LAVAL, QC / ACCESSWIRE / February 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Dec 22, 2022 05:59 am ET

First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans

LAVAL, QC, Dec. 22, 2022 /CNW Telbec/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLOTM (tazarotene lotion, 0.045% w/w), is now available to patients through the provincial public drug plans of Quebec, Ontario, Alberta and Saskatchewan, as well as the federal government's Non-Insured Health Benefits (NIHB) drug plan, which serves Canada's First Nations and Inuit populations.1

Dec 02, 2022 08:00 am ET

Bausch Health Wins DUOBRII(R) and BRYHALI(R) Patent Infringement Case

LAVAL, QB / ACCESSWIRE / December 2, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US LLC. According to the ruling, the District Court found all the asserted patents valid and infringed. The current decision will serve to prevent approval of Padagis BRYHALI® and DUOBRII® generics until patent expiry in 2031 and 2036, respectively.

Dec 01, 2022 08:00 am ET

Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider

LAVAL, QC / ACCESSWIRE / December 1, 2022 / Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), today announced the launch of a series of social media and digital initiatives to raise awareness during Constipation Awareness Month in December. The initiatives will discuss constipation diseases, including opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It is estimated that approximately up to 80% of

Nov 29, 2022 05:50 pm ET

Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents

LAVAL, QC / ACCESSWIRE / November 29, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subs

Nov 17, 2022 12:06 pm ET

IIROC Trade Resumption - BHC

TORONTO, Nov. 17, 2022 /CNW/ - Trading resumes in:

Nov 17, 2022 12:02 pm ET

IIROC Trading Halt - BHC

TORONTO, Nov. 17, 2022 /CNW/ - The following issues have been halted by IIROC:

Nov 04, 2022 08:00 am ET

Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022

LAVAL, QC / ACCESSWIRE / November 4, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ("Salix"), today announced one de novo abstract that is being presented at The Liver Meeting® 2022, organized by the American Association for the Study of Liver Diseases (AASLD), which is taking place November 4-8 in Washington, D.C.

Nov 03, 2022 07:00 am ET

Bausch Health Announces Third-Quarter 2022 Results

LAVAL, QC / ACCESSWIRE / November 3, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third-quarter 2022 financial results.

Nov 01, 2022 08:00 am ET

Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference

Nine Poster Presentations Include New Analyses of SILIQ® and JUBLIA®

Oct 31, 2022 08:00 am ET

Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge

New Educational Resource Designed to Help Support the Podiatry Community

Oct 24, 2022 08:00 am ET

Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting

LAVAL, QC / ACCESSWIRE / October 24, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ("Salix"), today announced four posters and one abstract featuring data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology® (ACG) 2022 Annual Scientific Meeting, which is taking place October 21-26 in Charlotte, North Carolin

Oct 20, 2022 08:00 am ET

Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference

Eleven Poster Presentations Include New Analyses of ARAZLO®, DUOBRII®, and IDP-126 Gel

Oct 13, 2022 08:00 am ET

Bausch Health to Announce Third Quarter 2022 Results on Nov. 3

LAVAL, QC / ACCESSWIRE / October 13, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("Bausch Health") will release its third quarter financial results on Thursday, Nov. 3, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Sep 23, 2022 06:59 am ET

Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

- RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older

Sep 08, 2022 04:45 pm ET

Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations

LAVAL, Quebec, Sept. 8, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") clarified today certain provisions related to its previously announced offers (the "Exchange Offers") to exchange the existing senior notes (the "Existing Senior Notes") for new secured notes (the "New Secured Notes") and related solicitation of consent (the "Consent Solicitation") pursuant to the terms described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated Aug. 30, 2022 (the "Exchange Offer Memorandum").

Sep 08, 2022 04:45 pm ET

Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations

LAVAL, Quebec, Sept. 8, 2022 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") clarified today certain provisions related to its previously announced offers (the "Exchange Offers") to exchange the existing senior notes (the "Existing Senior Notes") for new secured notes (the "New Secured Notes") and related solicitation of consent (the "Consent Solicitation") pursuant to the terms described in an Exchange Offer Memorandum and Consent Solicitation Statement, dated Aug. 30, 2022 (the "Exchange Offer Memorandum").

Sep 02, 2022 05:15 pm ET

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index

TORONTO, Sept. 2, 2022 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index and S&P/TSX 60 Index prior to the open of trading on Monday, September 19, 2022:

Aug 30, 2022 11:28 pm ET

Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes

LAVAL, Quebec, Aug. 30, 2022 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ( "Company") announced today that it has commenced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors, the "Maximum New Secured Notes Amount") of new secured notes, comprised of (i) up to $2.5 billion in aggregate principal amount (the "Maximum First Lien Notes Amount") of new 11.00% First Lien Secured Notes due 2028 (the "New Firs

Aug 30, 2022 11:28 pm ET

Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes

LAVAL, Quebec, Aug. 30, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ( "Company") announced today that it has commenced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors, the "Maximum New Secured Notes Amount") of new secured notes, comprised of (i) up to $2.5 billion in aggregate principal amount (the "Maximum First Lien Notes Amount") of new 11.00% First Lien Secured Notes due 2028 (the "N

Jul 28, 2022 10:51 am ET

IIROC Trading Halt - BHC

TORONTO, July 28, 2022 /CNW/ - The following issues have been halted by IIROC:

Jul 28, 2022 10:33 am ET

IIROC Trade Resumption - BHC

TORONTO, July 28, 2022 /CNW/ - Trading resumes in:

Jul 28, 2022 10:30 am ET

IIROC Trading Halt - BHC

TORONTO, July 28, 2022 /CNW/ - The following issues have been halted by IIROC:

Jul 28, 2022 10:18 am ET

IIROC Trading Halt - BHC

TORONTO, July 28, 2022 /CNW/ - The following issues have been halted by IIROC:

Jul 28, 2022 10:12 am ET

IIROC Trade Resumption - BHC

TORONTO, July 28, 2022 /CNW/ - Trading resumes in:

Jul 28, 2022 10:12 am ET

IIROC Trading Halt - BHC

TORONTO, July 28, 2022 /CNW/ - The following issues have been halted by IIROC:

Jul 28, 2022 10:03 am ET

IIROC Trade Resumption - BHC

TORONTO, July 28, 2022 /CNW/ - Trading resumes in:

Oct 28, 2021 06:59 am ET

The First and Only Tazarotene Lotion indicated for Acne Vulgaris in Patients 10 Years of Age and Older, ARAZLO™ now Available for Patients by Prescription across Canada

Shown to provide strong efficacy with good tolerability profile

Oct 04, 2021 07:05 am ET

Clearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple presentations...

Aug 04, 2021 06:55 am ET

Health Canada Approves ARAZLO™ (Tazarotene) Lotion, 0.045%, First Such Lotion Treatment For Acne Vulgaris

Shown to provide strong efficacy with good tolerability profile

May 05, 2021 06:55 am ET

Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI™

LAVAL, QC, May 5, 2021 /CNW Telbec/ - Bausch Health, Canada, which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced that Health Canada has approved the use of BRYHALI (Halobetasol Propionate Lotion 0.01% w/w), a high to super-high potency topical corticosteroid indicated for Corticosteroid-Responsive Dermatoses and the topical treatment of plaque psoriasis.i Some of the most "commonly-encountered skin disorders under the Corticosteroid-Responsive Dermatoses umbrella include seborrheic dermatitis and eczematous dermatoses such

May 03, 2021 07:05 am ET

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New...

Feb 08, 2021 07:05 am ET

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

Dec 01, 2020 05:55 am ET

Bausch + Lomb Announces Additional Expanded Public Coverage for (Pr)VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024% w/w) in Canada

PrVYZULTA® Added Under British Columbia, North West Territories, the Yukon and Veteran Affairs Plans LAVAL, QC, Dec. 1, 2020 /CNW/ - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), announced that PrVYZULTA® (latanoprostene bunod ophthalmic solution, 0.024% w/w), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, now has expanded public drug program reimbursement in Canada in the jurisdictions of British Columbia, North West Territories, the Yukon and Veteran Aff

Nov 10, 2020 05:55 am ET

Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII™ - a Novel Topical Antipsoriatic Prescription Drug

DUOBRII is a topical antipsoriatic medication introduced in Canada1 Positive CADTH recommendation moves DUOBRII closer to federal, provincial and territorial drug plan reimbursement DUOBRII provides the combined action of two compounds, halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug1 Formulated with PRISMATREX™, a proprietary technology, DUOBRII lotion improves the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis1 DUOBRII is manufactured for distribution throughout Canada and the United States at the Company's Que

Oct 20, 2020 06:55 am ET

Emerade™ (epinephrine 0.3 mg and 0.5 mg) now available in Canada

For the first time, Canadians managing emergency anaphylaxis have a new option with Emerade 0.5 mg dose auto-injector

Oct 13, 2020 07:00 am ET

Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million

Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that management will host an investor conference call to discuss the company’s...

Sep 24, 2020 07:00 am ET

Bausch + Lomb Announces Expanded Public Coverage for (Pr)VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024% w/w) in Canada

PrVYZULTA® Added Under Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador, and Federal Non-Insured Health Benefits (NIHB) Plans LAVAL, QC, Sept. 24, 2020 /CNW Telbec/ - Bausch + Lomb., a leading global eye health business of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), announced that PrVYZULTA® (latanoprostene bunod ophthalmic solution, 0.024% w/w), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, now has expanded public drug program reimbursement in the provinces of A

Sep 23, 2020 07:05 am ET

Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina

Sep 02, 2020 06:55 am ET

Now Available in Canada - Bausch Health, Canada Launches First of its Kind, Topical Antipsoriatic Agent in Almost Twenty Years

Formulated with PRISMATREX™, a proprietary technology, DUOBRII™ lotion improves the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis.

Jun 11, 2020 07:00 am ET

Health Canada Issues Notice of Compliance for Bausch Health's DUOBRII™

TOPICAL COMBINATION IMPROVING THE SIGNS AND SYMPTOMS OF PLAQUE PSORIASIS IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS FORMULATED WITH PROPRIETARY PRISMATREX™ TECHNOLOGY i

Dec 19, 2019 03:01 pm ET

Bausch + Lomb Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024%) Now Publicly Covered Under the Ontario Public Drug Benefit (ODB) Program

LAVAL, QC, Dec. 19, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), today announced that VYZULTA® (latanoprostene bunod ophthalmic solution, 0.024%), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, will be listed as a limited use product under the Ontario Drug Benefit (ODB) Formulary.ii The product will be added to formulary on Dec. 20, 2019.

Dec 13, 2019 04:15 pm ET

Quarterly S&P/TSX Composite Index Review - December 2019

TORONTO, Dec. 13, 2019 /CNW/ -

Oct 28, 2019 04:01 pm ET

Ahead of World Psoriasis Day, Bausch Health, Canada announces that SILIQ® (brodalumab) is now covered on most drug benefit formularies in Canada

Decision by majority of provincial governments to publicly list the drug ensures improved treatment access for nearly 800,000 Canadians currently living with plaque psoriasis1,2

Oct 17, 2019 10:15 am ET

Bausch Health Announces Updated Health Canada Safety Information for ELIDEL®

TOPICAL ATOPIC DERMATITIS TREATMENT, ELIDEL® NOW AVAILABLE FOR CHILDREN THREE MONTHS AND OVER

Apr 25, 2019 01:29 pm ET

IIROC Trade Resumption - BHC

TORONTO, April 25, 2019 /CNW/ - Trading resumes in:

Apr 25, 2019 01:16 pm ET

IIROC Trading Halt - BHC

TORONTO, April 25, 2019 /CNW/ - The following issues have been halted by IIROC:

Jan 08, 2019 06:30 am ET

Bausch Health's Canadian business positioned for growth in 2019

LAVAL, QC, Jan. 8, 2019 /CNW Telbec/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is positioned for growth in Canada in 2019 under a new name, Bausch Health, Canada inc. with a strong pipeline of products and a well-established manufacturing presence in the country.

Jan 03, 2019 06:30 am ET

Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma

LAVAL, QC, Jan. 3, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health (NYSE : BHC) (TSX : BHC) today announced that on December 27, 2018, Health Canada issued the Notice of Compliance (NOC) for VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%). VYZULTA™, the first prostaglandin analog with one of its metabolites being Nitric Oxide (NO), is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.i VYZULTA™ is the first new innovative treatment for open-angle

Sep 27, 2018 07:45 am ET

Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (“Salix”), one of...

Aug 20, 2018 07:00 am ET

RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it has received a...

You are here

Bausch Health Companies Inc. (T:BHC*CA)

Business Focus: Pharmaceuticals (NEC)